secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0000950170-24-035365
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics enters new ATM facility with B. Riley; FDA delays OPC1 study start
--------------------------------------------------------------------------------

- Entered Sales Agreement with B. Riley Securities to sell up to $6.7M in common shares via at-the-market offering; 3% commission.
- Terminated prior ATM with Cantor Fitzgerald; prior program sold approximately $6.66M in shares.
- FDA review of OPC1 IND for spinal cord injury ongoing; requested not to initiate DOSED study until feedback expected by April 26, 2024.
- Initial FDA clinical information request resolved; company aims to open first DOSED study site in Q2 2024.
- No change to previously guided timeline for study initiation; no additional activities required to address FDA request.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/0000950170-24-035365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/lctx-20240312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer